This bill amends Florida’s Medicaid statutes to create a specific exception to step-therapy prior authorization for drugs used to treat serious mental illness. It defines “serious mental illness” to include bipolar disorders, major depressive disorder, obsessive-compulsive disorder, psychotic disorders, schizoaffective disorder, schizophrenia, and related conditions. Under the bill, the Agency for Health Care Administration must approve a drug product without requiring step-therapy when a prescribing physician provides additional written medical or clinical documentation showing medical necessity, including when the patient has previously used the medication, alternatives have failed, or no acceptable preferred-drug-list option exists.
The bill also makes conforming changes to Medicaid drug-management and third-party liability provisions, and it directs the agency to account for the bill’s fiscal impact in Medicaid managed care and long-term care managed care rates effective October 1, 2025. In practical terms, the measure narrows the agency’s ability to force Medicaid recipients with serious mental illness through step-therapy sequences before accessing a needed medication, while leaving the broader Medicaid preferred drug list and prior authorization framework in place for other drugs and conditions.
Impact
The bill amends sections 409.901, 409.912, and 409.910, Florida Statutes. Its main legal effect is to require Medicaid coverage approval without step-therapy for certain medications treating serious mental illness when medical-necessity documentation is provided, thereby limiting the agency’s discretion under existing step-edit and prior authorization rules for that subset of patients and drugs. It also updates a cross-reference in the Medicaid third-party liability statute and requires AHCA to incorporate the bill’s rate impact into managed care capitation rates beginning October 1, 2025.
Sentiment
The available vote history suggests strong support: the Senate Health Policy committee approved the bill unanimously, 9-0. No committee transcript excerpts were provided, but the bill’s structure indicates a policy balance between Medicaid cost controls and access to treatment for serious mental illness. Overall, the measure appears to have been received favorably as a targeted patient-access exception rather than a broad rollback of Medicaid utilization management.
Contention
The main point of contention is the tension between Medicaid cost containment and clinical access. Supporters are likely to favor the bill because it reduces barriers for patients with serious mental illness who may be harmed by delays caused by step therapy. Potential opponents or skeptics would be those concerned about increased Medicaid spending, reduced use of preferred drugs, and the administrative burden of documenting medical necessity. The bill tries to address those concerns by limiting the exception to serious mental illness and preserving the agency’s broader prior authorization and preferred drug list authority for other medications.